IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
Portfolio Pulse from
IDEAYA Biosciences has announced the nomination of IDE251, a potential first-in-class KAT6/7 dual inhibitor, as a development candidate. IDE251 targets 8p11 amplification tumors in breast and lung cancers, showing promising anti-tumor activity in preclinical models. An IND submission is planned for 2025.
December 16, 2024 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IDEAYA Biosciences has nominated IDE251, a potential first-in-class KAT6/7 dual inhibitor, as a development candidate for breast and lung cancers with 8p11 amplification. The drug has shown promising preclinical results, and an IND submission is planned for 2025.
The nomination of IDE251 as a development candidate is a significant milestone for IDEAYA Biosciences, indicating progress in their pipeline. The promising preclinical results and the potential first-in-class status of IDE251 could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100